Akums Drugs & Pharmaceuticals Ltd

Akums Drugs & Pharmaceuticals Ltd is rated 'Hold' by MarketsMOJO, with this rating last updated on 13 August 2026. However, the analysis and financial metrics discussed here reflect the stock's current position as of 16 September 2026, providing investors with an up-to-date view of the company’s fundamentals, returns, and market standing.

Akums Drugs & Pharmaceuticals Ltd is rated 'Hold' by MarketsMOJO, with this rating last updated on 13 August 2026. However, the analysis and financial metrics discussed here reflect the stock's current position as of 05 September 2026, providing investors with an up-to-date view of its fundamentals, returns, and market performance.

Surging past its previous peak, Akums Drugs & Pharmaceuticals Ltd reached a fresh 52-week high of Rs 788.95 on 1 Sep 2026, marking a remarkable 69.17% gain over the past year despite a broadly weakening Sensex. This milestone underscores the stock’s robust price momentum and technical alignment across multiple timeframes.

Surging past its previous peak, Akums Drugs & Pharmaceuticals Ltd touched a new 52-week high of Rs 783.9 on 31 Aug 2026, marking a remarkable 71.65% gain over the past year. This rally stands in stark contrast to the broader market's subdued performance, with the Sensex down 3.57% over the same period.

From a 52-week low of Rs 410.1 to a fresh high of Rs 783.8 on 25 Aug 2026, Akums Drugs & Pharmaceuticals Ltd has surged 56.75% over the past year, significantly outperforming the Sensex which declined by 5.48% in the same period. This milestone reflects a powerful momentum driven by a confluence of technical indicators signalling strength across multiple timeframes.

Akums Drugs & Pharmaceuticals Ltd is rated 'Hold' by MarketsMOJO, with this rating last updated on 13 August 2026. While the rating was revised on that date, the analysis and financial metrics discussed here reflect the stock's current position as of 25 August 2026, providing investors with an up-to-date perspective on the company’s fundamentals, valuation, financial trends, and technical outlook.

Akums Drugs & Pharmaceuticals Ltd has seen its investment rating downgraded from Buy to Hold following a comprehensive reassessment of its quality, valuation, financial trend, and technical parameters. While the company’s recent quarterly financial performance has been robust, elevated valuation metrics and mixed technical signals have tempered enthusiasm among analysts, prompting a more cautious stance.

Akums Drugs & Pharmaceuticals Ltd is rated 'Buy' by MarketsMOJO, with this rating last updated on 8 August 2026. However, the analysis and financial metrics discussed here reflect the stock's current position as of 13 August 2026, providing investors with the latest insights into its performance and outlook.

With a 57.24% gain over the past year, Akums Drugs & Pharmaceuticals Ltd has surged to a fresh 52-week high of Rs 775.45 on 12 Aug 2026, outpacing the Sensex which declined by 2.85% over the same period. This milestone caps a sustained rally fuelled by a confluence of bullish technical indicators and robust price momentum.

With a decisive break above Rs 760.5 on 11 Aug 2026, Akums Drugs & Pharmaceuticals Ltd has reached a fresh 52-week high, extending its impressive rally that has delivered 58.48% returns over the past year. This milestone comes amid a backdrop of strong technical momentum and sustained outperformance relative to the broader market indices.

Akums Drugs & Pharmaceuticals Ltd has witnessed a notable shift in its valuation parameters, moving from an attractive to an expensive rating. This change, reflected in key metrics such as the price-to-earnings (P/E) and price-to-book value (P/BV) ratios, signals a recalibration of price attractiveness amid robust stock performance and evolving market dynamics.

The Sensex edged up 0.09% on 10 Aug 2026, but Akums Drugs & Pharmaceuticals Ltd outpaced the broader market with a robust 7.68% gain, reaching an intraday high of Rs 750. This 7.18 percentage-point outperformance over its Pharmaceuticals & Biotechnology sector peers highlights a distinctly stock-specific rally rather than a market-wide lift.

Surging past its previous peak, Akums Drugs & Pharmaceuticals Ltd touched a fresh 52-week high of Rs 750 on 10 Aug 2026, marking a remarkable 53.0% gain over the past year and outpacing the Sensex’s modest decline of 1.72% during the same period.

Akums Drugs & Pharmaceuticals Ltd has experienced a notable shift in its valuation parameters, moving from an attractive to a fair valuation grade. This change reflects evolving market perceptions amid a challenging Pharmaceuticals & Biotechnology sector, with the company’s price-to-earnings (P/E) and price-to-book value (P/BV) ratios now aligning more closely with historical and peer averages. Investors are advised to consider these valuation dynamics alongside Akums’ robust operational metrics and recent market performance.

Akums Drugs & Pharmaceuticals Ltd is rated 'Hold' by MarketsMOJO, with this rating last updated on 10 April 2026. However, the analysis and financial metrics discussed here reflect the stock's current position as of 02 August 2026, providing investors with an up-to-date perspective on its performance and outlook.

Akums Drugs & Pharmaceuticals Ltd has witnessed a notable shift in its valuation parameters, moving from a fair to an attractive rating. This change reflects a more compelling price proposition for investors, especially when analysed against historical averages and peer benchmarks within the Pharmaceuticals & Biotechnology sector.

Akums Drugs & Pharmaceuticals Ltd is rated 'Hold' by MarketsMOJO. This rating was last updated on 10 April 2026, reflecting a shift from the previous 'Sell' grade. However, the analysis and financial metrics discussed here are based on the stock's current position as of 22 July 2026, providing investors with the latest insights into the company’s performance and outlook.